News

Weight-Loss Drugs Telehealth Platform Hims & Hers Hit With New Lawsuit
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...
USA Herald1d
Hims & Hers Executives Face Lawsuit Over Knockoff Wegovy Sales
Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...
Why Hims & Hers Management Might Be Its Most Valuable Asset
Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...
Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With Novo
Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...
Market on Mute? Not for These 10 Stocks With Surprising Gains
Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 percent, the S&P 500 ...
The unlikely pact and breakup of a drugmaker and a telehealth star
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
Hims CEO reveals details of Novo Nordisk partnership breakdown - WaPo
Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...